Open the Gate – My Disclosure: The Dark Side of Clinical Trials Episode 4
(caution) These pictures are copyright protected by 2026, Medical enhance co, ltd and Kico Aizaki, Dear readers, I am Kico Aizaki This post is a continuation of my previous blog post. I talked to three detectives from the security intelligence police department regarding the flow of money in clinical trials. They asked me the same question: "Why is there a distinction between disclosed obligation money and non-disclosed obligation money?" I answered that cooperating medical institutions, SMOs (Site Management Organizations), and IRBs (Institutional Review Boards) must disclose payments from pharmaceutical companies based on the contracts between the pharmaceutical company and each institution. However, CROs (Contract Research Organizations) and CRAs (Clinical Research Associates) have no duty to disclose payment amounts from pharmaceutical companies. CROs work with many vendors, academic doctors, and suppliers. Furthermore, CROs and CRAs do not disclose the detailed breakdown...